Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.07 USD
-0.02 (-1.83%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.06 -0.01 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
Biofrontera Inc. [BFRI]
Reports for Purchase
Showing records 21 - 40 ( 58 total )
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Increases Ameluz-PDT Salesforce By Almost 30% As Alluded To On 4Q22 Call
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Commercial Infrastructure Growing, New Sales Hires Coming in 1H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Released Preliminary 4Q22 & 2022 Revenue, Future Ameluz Label To Expand
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Phase 3 Ameluz-PDT Trial For AK On Extremities, Neck, And Trunk
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Maximizing Current Salesforce, Lowers 2022 Guidance Due to Timing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Aggressively Showcasing Ameluz-PDT to Increase Dermatologist Adoption
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Preannounces $4.3M 3Q22 Revenue; Reiterates YoY Revenue Guidance of 30%
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Recent Management Meeting Anecdotes that Underscore Ameluz''s Potential
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Progress Across the Board, Maintains 2022 Revenue Guidance
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J